Fig. 7: ptCRC11 and mCRC11 PDOs demonstrate different phenotypic response to QPOP-optimised combinations. | npj Precision Oncology

Fig. 7: ptCRC11 and mCRC11 PDOs demonstrate different phenotypic response to QPOP-optimised combinations.

From: A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Fig. 7

a Bliss synergy maps for decitabine and vorinostat in ptCRC11 and b mCRC11 over the entire dose matrix. Bliss synergy scores are represented as means of the entire search space ± 95% confidence interval. c Synergy landscape for oxaliplatin-SN-38 in ptCRC11 and d mCRC11 over the entire dose matrix. Bliss synergy scores are represented as means of the entire search space ± 95% confidence interval. e Dose-response curves of decitabine and vorinostat in ptCRC11 and f mCRC11 organoids when administered singly and in combination. g Dose-response curves of ptCRC11 and h mCRC11 PDOs following oxaliplatin and SN-38 treatment alone and concurrently.

Back to article page